Clinical trial
A Cancer Research UK Phase I/IIa Trial of HTL0039732, Given Orally as Monotherapy and in Combination With Immunotherapy or Other Approved Therapies in Participants With Advanced Solid Tumours
NCT05944237 is registered in ClinicalTrials.gov with Cancer Research UK as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Cancer Research UK Phase I/IIa Trial of HTL0039732, Given Orally as Monotherapy and in Combination With Immunotherapy or Other Approved Therapies in Participants With Advanced Solid Tumours
- Lead sponsor
- Cancer Research UK
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- August 2, 2023
- Completion date
- December 31, 2028
- Enrollment
- 150 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
colorectal neoplasms, esophageal neoplasms, head and neck neoplasms, kidney neoplasms, lung neoplasms, mesothelioma, malignant, neoplasms, pancreatic neoplasms, pheochromocytomas, prostatic neoplasms, castration-resistant, sarcoma, stomach neoplasms, urinary bladder neoplasms, uterine cervical neoplasms